Baseline clinical and treatment characteristics of 109 patients with high-risk DLBCL in CMR receiving atezolizumab consolidation
| Baseline variable . | No. of patients . | % . |
|---|---|---|
| Total | 109 | 100 |
| Sex | ||
| Male | 64 | 59 |
| Female | 45 | 41 |
| Median age, IQR | 64 | (54-70) |
| Ann Arbor stage | ||
| II | 1 | 1 |
| III | 21 | 19 |
| IV | 87 | 80 |
| IPI score | ||
| 3 | 69 | 63 |
| 4-5 | 40 | 37 |
| Histology | ||
| Large BCL | ||
| DLBCL NOS | 97 | 89 |
| Transformed FL | 4 | 4 |
| Unclassifiable | 3 | 3 |
| EBV-positive DLBCL | 2 | 2 |
| Follicular lymphoma I-II | 2 | 2 |
| NLPHL | 1 | 1 |
| R-CHOP | ||
| 6 cycles | 104 | 95 |
| 8 cycles | 5 | 5 |
| CNS prophylaxis | ||
| MTX intrathecally | 39 | 36 |
| No prophylaxis | 70 | 64 |
| Baseline variable . | No. of patients . | % . |
|---|---|---|
| Total | 109 | 100 |
| Sex | ||
| Male | 64 | 59 |
| Female | 45 | 41 |
| Median age, IQR | 64 | (54-70) |
| Ann Arbor stage | ||
| II | 1 | 1 |
| III | 21 | 19 |
| IV | 87 | 80 |
| IPI score | ||
| 3 | 69 | 63 |
| 4-5 | 40 | 37 |
| Histology | ||
| Large BCL | ||
| DLBCL NOS | 97 | 89 |
| Transformed FL | 4 | 4 |
| Unclassifiable | 3 | 3 |
| EBV-positive DLBCL | 2 | 2 |
| Follicular lymphoma I-II | 2 | 2 |
| NLPHL | 1 | 1 |
| R-CHOP | ||
| 6 cycles | 104 | 95 |
| 8 cycles | 5 | 5 |
| CNS prophylaxis | ||
| MTX intrathecally | 39 | 36 |
| No prophylaxis | 70 | 64 |
EBV, Epstein-Barr virus; FL, follicular lymphoma; MTX, methotrexate; NLPHL, nodular lymphocyte-predominant Hodgkin lymphoma; NOS, not otherwise specified.